Abstract
Breast cancer is the most common cancer in women in the Western world and in most Western countries and the second leading cause of cancer-related death in women with an age-adjusted incidence of 117.7 women per year in 2004.1 The National Cancer Institute estimates 178,480 women will be diagnosed with breast cancer and 40,640 women will die of breast cancer in 2007 in the United States, most of them of progressive metastatic disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ries LAG, Melbert D, Krapacho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2004. Bethesda, MD:National Cancer Institute, http://seer.cancer.gov/csr/19752004/, posted to the SEER web site 2007.
http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page4/.
Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:1601–1602.
Avril N, Adler LP. F-18 Fluorodeoxyglucos positron emission tomography imaging for primary breast cancer and loco-regional staging. PET Clinics 2006;1:1–14.
Eubank WB. Diagnosis of recurrent and metastatic disease using F-18 fluorodeoxyglucose-positron emission tomography. PET Clinics 2006;1:15–24.
Quon A, Gambhir SS. FDG-PET and beyond: Molecular breast cancer imaging. J Clin Oncol 2005;23:1664–1673.
Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006;79:32–36.
Scheidhauer K, Walter C, Seedmann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 2004;31(Suppl. 1):S70–S79.
Wahl RL, Siegel BA, Coleman R, Gatsonis CG. A prospective multicentre study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277–285.
Aarsvold JN, Alzaraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. Semin Nucl Med 2005;35:116–128.
Iagaru A, Masamed R, Keesara H, Conti PS. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 2007;21:33–38.
Tafra L. Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 2007;14:3–13.
Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84–99.
Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and skeletal metastases. Semin Nucl Med 2005;35:135–142.
Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: Sequential [18F] Fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of skeletal metastases in breast cancer. J Clin Oncol 2007;25:3440–3447.
Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T,Nishimura T. Pitfalls of FDG-PET for the diagnosis of osteoblastic skeletal metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253–1258.
Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 2004;31(Suppl.1): S135–S142.
Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254–262.
Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005;11:204–209.
Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105–112.
Suárez M, Pérez-Castejón MJ, Jiménez A, Romper M, Ruiz G, Montz R, Carreras JL. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002;46:113–121.
Eubank WB, Mankoff DA, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seumour M, Livingston R. Impact of [18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. Am J Roentgenol 2004;183:479–486.
Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratio O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imag Biol 2005;7:369–376.
Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545–2551.
Belli P, Constantini M, Romani M, Marano P, Pastore G. Magnetic resonance imaging in breast cancer recurrence. Breast Cancer Res Treat 2002;73:223–235.
Goerres GW, Michel SCA, Fehr MK, Kaim AH, Steinert HC, Seifert B, von Schulthess GK, Kubik-Hoch RA. Follow-up of women with breast cancer: Comparison between MRI and FDG PET. Eur Radiol 2003;13:1635–1644.
Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and breast for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224–239.
Biersack HJ, Bender H, Palmedo H.FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 2004;31(Suppl. 1):S112–S117.
Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002;43:325–329.
Schwartz JD, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144–1150.
Berriolo-Riedinger A, Touzery C, Riedinger J-M, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915–1924.
Heron DE, Beriwal S, Avril N. FDG-PET and PET/CT in radiation therapy simulation and management of patients who have primary and recurrent breast cancer. PET Clinics. 2006;1:39–49.
Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, Keil K, Komaki R, Larson SM, Mankoff DA, Rozenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN task force report: Positron emission tomography (PET/Computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5 (Suppl 1): S1–S22. www/nccn.org/professionals/physician_gls/f_guidelines.asp
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N , Einhorn LH, Suh WW, Samson D, Delbeke D,Gorman M, Shields AF. Recommendations for the Use of FDG (fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) Positron emission tomography in oncology. J Nucl Med 2008;49:480–508.
Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET:Histopathologic comparison. Radiology 2004;230:417–422.
Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, Inbar M, Metser U. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006;33:541–552.
Pickel H, Reich O. Ovarian metastases of breast cancer. CME Journal of Gynecologic Oncology 2004;9:129–132.
Hann LE, Lui DM, Shi W, Bach AM, Selland D-L, Castiel M. Adnexal masses in women with breast cancer: US findings with clinical and histopathologic correlation. Radiology 2000;216:242–247.
Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, Bomanji JB, Ell PJ. The impact of 18F-FDG PET/CT in patients with hepatic metastases. Eur J Nucl Med Mol Imaging 2007;34:1906–1914.
Turken O, NarIn Y, DemIrbas S, Onde ME, Sayan O, KandemIr EG, Yaylac IM, Ozturk A. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003;5:R110–R113.
Agarwal DP, Soni TP, Sharma OP, Sharma S. Synchronous malignancies of breast and thyroid gland: A case report and review of literature. J Cancer Res Ther 2007;3:172–173.
Hathaway PB, MAnkoff DA, MAravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, Cortese AA, Hayes CE, Moe RE. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer:Preliminary experience. Radiology 1999;210:807–814.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496–507.
Acknowledgments
The authors are thankful to Prof. Peter J. Ell for critically reviewing this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ben-Haim, S., Prakash, V. (2010). Breast Cancer. In: Delbeke, D., Israel, O. (eds) Hybrid PET/CT and SPECT/CT Imaging. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92820-3_6
Download citation
DOI: https://doi.org/10.1007/978-0-387-92820-3_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-92819-7
Online ISBN: 978-0-387-92820-3
eBook Packages: MedicineMedicine (R0)